

VIVALIS SECURES AN IMPORTANT PATENT COVERING ITS EBx[®] PLATFORM

Nantes (France) –September 23, 2008 – VIVALIS (NYSE Euronext: VLS) announced today that it has secured major patent protection for its EBx[®] platform in Europe and in Australia.

The protection of its intellectual property represents a strategic investment for VIVALIS to protect its business. The company is building up an extensive patents portfolio word-wide securing each potential EBx[®] application.

The European Patent Office and the Australian Patent Office respectively granted patents N° EP1,483,36 9 and N° AU2003227820 related to the process of establishment of avian embryonic stem cell derived EBx[®] cell line, and on the avian cell line obtained by such process, that includes the widely licensed duck EB66[®] cell line. The granted patents also claim the use of avian EBx[®] cells for the production of biologicals, such as human and animal viral vaccines and recombinant proteins for example.

Regarding the European patent EP1,483,369, VIVALIS validated separate patents in 24 different European countries.

So far, VIVALIS portfolio comprised 3 exclusive licenses related to stem cells technology with the North Carolina State University (USA) and INRA / CNRS / ENS Institutes (France), and it has secured 47 granted patents and 36 patent applications in more than 35 countries in the world in order to protect its breakthrough technology. In the coming years, VIVALIS will continue to strengthen this important patents portfolio of patents all over the world.

"The company continues to build on its intellectual property rights position. These patents that protect VIVALIS EBx[®] platform are major milestones for VIVALIS and its licensing partners. They further strengthen VIVALIS' patent position in the field of cell-based production of biologicals", said Franck GRIMAUD, VIVALIS CEO.

Next press release:

November 13, after Euronext market closing: 3rd quarter sales

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. Vivalis receives up front, milestones and royalties payments on its licensees net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66[®] cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives up front, milestones, and royalties payments on its licensees net sales.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial and SAFB Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

Euronext Paris Compartment C - FR0004056851
Reuters: **VLS.PA** – Bloomberg: **VLS FP**

Investor relations:

VIVALIS

Franck Grimaud, C.E.O.

Email: investors@vivalis.com

NewCap

Financial Communication Agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr